Evolva Holding SA
https://evolva.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Evolva Holding SA
FTC Tells Medtronic To Sell Intersect ENT Subsidiary To Avoid Monopoly
The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.
Medtronic Bolsters Sinus Portfolio With $1.1Bn Intersect ENT Buyout
Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.
Lupin Expects Respiratory Ramp Up From Fiscal '22
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
Lupin Expects Respiratory Ramp Up From Fiscal '22
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
Company Information
- Industry
- Biotechnology
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Allylix, Inc
- Arpida
- Evolva AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice